The goal of the T32 research training program in urologic oncology at Memorial Sloan-Kettering Cancer Center (MSKCC) is to train qualified clinician-scientists to be independent investigators in translational research and to progress to full-time academic positions. Dedicated research training in urologic oncology is essential to the mission of the National Cancer Institute (NCI) to eliminate suffering and death from cancer: genitourinary cancers comprise nearly one third of all non-skin cancers and cause 10% of all cancer deaths in the US. T32 fellows gain direct experience in biomedical research by working full-time for 2 years with established basic and translational research scientists. Fellows are also required to participate in structured, multidisciplinary conferences and to present their work at MSKCC seminars and national meetings. T32 preceptors represent the departments of Surgery, Epidemiology and Biostatistics, Medicine, Radiology, and Pathology, as well as 4 of the major research programs at the Sloan-Kettering Institute: Cell Biology, Immunology, Molecular Biology, and Molecular Pharmacology and Chemistry. Areas of research include cancer genetics;signals and pathways involved in the control of cell proliferation;protein targeting;tumor immunology, immunotherapy, and clinical therapeutics, among others. Although fellows may also undertake 1 year of clinical training, they have no clinical responsibilities during their research years unless it is integral to their research project. Most T32 fellows spend 2.5 to 3.5 years completing all research and clinical training. This T32 training grant will continue to support 4 postdoctoral fellows (typically 2 new and 2 continuing trainees) per year. All T32 candidates must have an MD, must have completed training in urology at a residency program approved by the Accreditation Council for Graduate Medical Education (ACGME), and must be board-eligible urologists. T32 fellows usually enter the program during PGY-6 or PGY-7.

Public Health Relevance

MSKCC's T32 program in urologic oncology trains qualified clinician-scientists for careers focused on eliminating suffering and death from urologic cancers, which comprise 31% of all non-skin cancers and cause 10% of all cancer deaths in the US. To date, 95% of the graduates have matriculated to faculty positions and are engaged in research aimed at understanding and overcoming these cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA082088-12
Application #
8128534
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
1999-09-01
Project End
2015-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
12
Fiscal Year
2011
Total Cost
$254,589
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Li, Qiang; Assel, Melissa; Benfante, Nicole et al. (2017) Clinical Outcomes in Patients with Panurothelial Carcinoma Treated with Radical Nephroureterectomy Following Cystectomy for Metachronous Recurrence. J Urol 198:546-551
Hsieh, James J; Manley, Brandon J; Khan, Nabeela et al. (2017) Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer. Semin Cell Dev Biol 64:98-106
Manley, Brandon J; Tennenbaum, Daniel M; Vertosick, Emily A et al. (2017) The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models. Urol Oncol 35:35.e1-35.e5
Winer, Andrew G; Vertosick, Emily A; Ghanaat, Mazyar et al. (2017) Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol 35:151.e9-151.e15
Tennenbaum, Daniel M; Manley, Brandon J; Zabor, Emily et al. (2017) Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Urol Oncol 35:532.e7-532.e13
Dong, Yiyu; Manley, Brandon J; Becerra, Maria F et al. (2016) Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. Eur Urol Focus :
Thong, Alan E; Petruzella, Stacey; Orlow, Irene et al. (2016) Accuracy of Self-reported Smoking Exposure Among Bladder Cancer Patients Undergoing Surveillance at a Tertiary Referral Center. Eur Urol Focus 2:441-444
Sankin, Alexander; Tin, Amy L; Mano, Roy et al. (2016) Impact of Ureteroscopy Before Nephroureterectomy for Upper Tract Urothelial Carcinoma on Oncologic Outcomes. Urology 94:148-53
Li, Qiang; Bagrodia, Aditya; Cha, Eugene K et al. (2016) Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma. Curr Urol Rep 17:12
Kaffenberger, Samuel D; Barbieri, Christopher E (2016) Molecular subtyping of prostate cancer. Curr Opin Urol 26:213-8

Showing the most recent 10 out of 191 publications